Sintalica Bioscience has received, through the University of Messina, authorisations from the Italian Ministry of Health pertaining to its drug development programme.
Clarify Pharma has acquired shares to the value of £250,000 in each of Atai Life Sciences and Compass Pathways as part of its investment strategy.
Mindset Pharma and PharmaAla have entered into an exclusive sales agreement for the sale and distribution of pharmaceutical-grade psilocybin.
Canadian non-profit TheraPsil has announced that patients and medical professionals from across Canada will be reaching out to Parliamentarians to raise awareness of the medical benefits...
A team at the Allen Institute for Brain Science, a division of the Allen Institute, has sent brain samples on a “trip” to gain insights into...
Colorado has voted to pass the Natural Medicine Health Act (Proposition 122) by 51.4%, which will see the decriminalisation and regulation of the use of psychedelic medicines.
Psychedelic-assisted therapy company Better U has created a Military Liaison Officer position to help expand access for veterans.
Collaborators of Tryp Therapeutics from the University of Michigan will present two scientific posters at the Society for Neuroscience conference.
How do treatments for mood and anxiety disorders derived from psilocybin exert their effects in the brain?
Beckley Psytech has dosed the first participant in its Phase 1 single-ascending dose (SAD) study of ELE-101 – a novel intravenous formulation of psilocin – with...